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OBJECTIVES: To evaluate the functional and histological effects of estrogen as a neuroprotective agent after a
standard experimentally induced spinal cord lesion.
METHODS: In this experimental study, 20 male Wistar rats were divided into two groups: one group with rats
undergoing spinal cord injury (SCI) at T10 and receiving estrogen therapy with 17-beta estradiol (4mg/kg)
immediately following the injury and after the placement of skin sutures and a control group with rats only
subjected to SCI. A moderate standard experimentally induced SCI was produced using a computerized device
that dropped a weight on the rat’s spine from a height of 12.5 mm. Functional recovery was verified with the
Basso, Beattie and Bresnahan scale on the 2nd, 7th, 14th, 21st, 28th, 35th and 42nd days after injury and by
quantifying the motor-evoked potential on the 42nd day after injury. Histopathological evaluation of the SCI
area was performed after euthanasia on the 42nd day.
RESULTS: The experimental group showed a significantly greater functional improvement from the 28th to the
42nd day of observation compared to the control group. The experimental group showed statistically significant
improvements in the motor-evoked potential compared with the control group. The results of pathological
histomorphometry evaluations showed a better neurological recovery in the experimental group, with respect
to the proportion and diameter of the quantified nerve fibers.
CONCLUSIONS: Estrogen administration provided benefits in neurological and functional motor recovery in rats
with SCI beginning at the 28th day after injury.
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The treatment of spinal cord injuries (SCI) remains challen-
ging; none of the available treatments are considered particu-
larly effective (1) and SCI is still considered an irreversible
condition (2). Although surgical mechanical stabilization is
performed in unstable spinal fractures (with poor results),
pharmacological treatments represent the most well-studied
experimental protocol (3,4). Many pharmacological agents have
been studied (2,4-6) and estrogen has shown consistent results
as a neuroprotective agent (7-10).
Estrogen inhibits inflammation and activates a variety of
cysteine proteases in animal models. Furthermore, estrogen
shows anti-inflammatory activity in the cascade of events
after SCI, including microglial activation, increased blood
flow to the injured tissue, increased anti-apoptotic protein
levels and attenuated post-traumatic influx of calcium, thus
acting as a neuroprotective agent (7,11-13).
More studies are necessary, however, to elucidate the role
of estrogen in the reduction of secondary lesions after spinal
cord trauma. Even if the spinal cord does not completely
recover, the patient’s quality of life can be improved through
smaller tissue repairs that allow minimal functional recovery.
Even if the patient cannot walk, their ability to regain control
of the sphincters or respiratory muscles and restore hand
function represent very important achievements.DOI: 10.6061/clinics/2015(10)08
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BASIC RESEARCH
No previous study has analyzed the functional and
histological effects of estrogen in SCI in a single experiment
in the same sample of rats. The objective of the present study
was to evaluate the functional and histological results of six
weeks of estrogen treatment immediately after a standard
experimentally induced spinal cord lesion in rats. Our
hypothesis was that estrogen would exhibit a neuroprotec-
tive effect that could be demonstrated by histological
outcomes and functional evaluations.
’ METHODS
Ethics, study design, animals and allocation
This was an experimental, controlled study with Wistar
rats that was performed in the laboratory of the Hospital
das Clínicas da Faculdade de Medicina da Universidade de
São Paulo Instituto de Ortopedia e Traumatologia (IOT-
HCFMUSP) (São Paulo, Brazil). The study protocol was
approved by the Institutional Review Board and we certify
that all applicable institutional and governmental regulations
concerning the ethical use of animals in experiments were
followed during the course of this research.
Twenty male Wistar rats were divided in two groups, both
of which were subjected to standard experimentally induced
spinal cord lesions with the NYU Impactor device as
described below. Ten animals received estrogen therapy
(with intraperitoneal 17-beta estradiol) under sedation and
the 10 rats in the control group were not treated. The sample
size was based on previous studies (4,5).
The allocation of the animals to each group was concealed
from the surgeon performing the experimental SCI (OL). The
researcher administrating the estrogen therapy was not blind
to the allocation because the animals in the control group did
not receive injections. However, the allocation was concealed
from the researchers who were involved in both the
histological and functional evaluations.
The 20- to 21-week-old rats, weighing 300 g to 420 g, were
all healthy, had a normal gait and were obtained from the
university vivarium. Five animals from the same litter were
housed in each cage in the laboratory, with adequate feeding
and hydration. The animals were manipulated and stimu-
lated to move before the experiment so that they could adapt
to contact with the researchers and to the motor function
evaluation after SCI. All experiments were performed at the
same time of the day in both groups to avoid interfering with
the day-night cycle. All rats were euthanized on the 42nd day
after the experiment.
Death after SCI, autophagic or mutilating behavior and
macroscopic spinal anomalies were the exclusion criteria for
our study. If the rats exhibited normal movement after the
experimental lesion (21 points on the Basso Beattie and
Bresnahan (BBB) scale) or there was a problem with the NYU
impactor, the animals were excluded from the analysis.
Anesthesia, laminectomy and SCI
Intraperitoneal injections of xylazine (10 mg/kg) and
ketamine (50 mg/kg), followed by subcutaneous injections
of lidocaine hydrochloride with epinephrine, were used for
anesthesia before the experiment. A veterinarian monitored
all of the procedures to ensure the absence of reflexes.
Surgery was performed using aseptic techniques.
A previously described protocol for weight-drop SCI (4,5)
was used to produce a moderate lesion. The lesion was
generated with the NYU Impactor (New York University
Spinal Cord Contusion System) and a 10-g impact rod from
a standardized height of 12.5 mm, which compressed the
spinal cord for 15 seconds. The lesion was produced at T10.
The experimental intervention: estrogen
injection
Estrogen was administered intraperitoneally as 17-beta
estradiol (Drogavet, Curitiba), only to animals in the study
group. A dose of 4 mg/kg was given immediately following
SCI, after skin sutures were applied (7-9), while the animal was
still under anesthesia and sedated. Estrogen was administered
by the veterinarian who was caring for the animals.
Animal care after SCI
After cleaning the surgical scar, a layer of topical ointment
(fibrinolysin, deoxyribonuclease and chloramphenicol) was
applied. The animals then immediately received cefazolin
sodium (Cezolin, BioChimico, Rio de Janeiro) intraperitone-
ally (5 mg/kg) as a prophylactic. Animals presenting an
infection (inflammatory signs such as purulent secretions or
abnormal urine) received an antibiotic for 10 days and were
excluded from the statistical analysis.
For pain relief, the rats in both groups were intramuscu-
larly administered a non-steroidal anti-inflammatory agent
(2 mg/kg of meloxicam, once daily, for 7 days), along with
tramadol hydrochloride (5 mg/100 g, once daily for 5 days).
The injections were administered in the deep muscles of the
lower limbs (thighs).
The animals’ bladders were manually emptied at least
twice daily until the animals regained bladder function. The
rats were housed in their original cages (40 60 cm for a
group of five), with food and water available ad libitum
(offered as soon as the animal was fully awake).
Functional and motor-evoked potential evaluations
Function was evaluated using the BBB scale (4,5) by two
trained evaluators who were blind to the animal allocation.
In the case of a disagreement, the lowest score between the
two was registered for statistical analysis. The BBB evalua-
tion took place on the 2nd, 7th, 14th, 21st, 28th, 35th and 42nd
days after SCI. The rats were stimulated to move by gentle
touches and the evaluations took four to five minutes per rat.
On the 42nd day after SCI, the rats were anesthetized (with
ketamine and xylazine, as described) and evaluated using the
evoked potential test (MEP) (7) through transcranial electrical
stimulation at the cortical level, with the responses captured at
the muscular level (Figure 1). The electrodes were positioned in
the semitendinosus and the biceps muscles of the thigh. The test
monitored the response to the stimulus for 100 ms at most. For
the average latency calculation, we used this maximum time of
observation when no response was observed and the amplitude
was recorded as zero. During observation of the response to
electrical stimulation, the latency and amplitude were recorded at
the time the signal was observed. The amplitude was registered
in millivolts and the latency was recorded in milliseconds.
The MEP and BBB tests were performed by a physician
blinded to the animal allocation, according to methods
described by others (6,14,15).
Euthanasia
All rats were sedated and anesthetized prior to euthanasia,
which took place on the 42nd day after the experiment.
Euthanasia consisted of transcardial perfusion with a
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4% paraformaldehyde solution and intravenous administration
of thiopental (65 mg/100 g) and potassium chloride.
Histological analysis
After euthanasia, the vertebral spine was exposed through
an extensive dorsal incision and a 2.5-cm segment of the
spinal cord from T8 to T12 was removed with scissors,
including the focus of the lesion. Visual macroscopic
evaluation of the spinal cord at the contusion site was
performed to check for any anomalies (exclusion criteria) (5).
The extracted segment was fixed and prepared for histolo-
gical analysis, as described by Cristante et al. (4).
Thoracotomy and laparotomy enabled the inspection of the
lungs, abdomen and bladder and the researcher was looking for
signs of empyema, condensation, a flaccid neurogenic bladder
(with increase in volume) or hyperemia and hematuria (5).
The fragments were fixed in formalin (10%), identified,
dehydrated in alcohol baths, diaphanized in xylol and
impregnated with paraffin. Five-micron-thick sections were
cut (1-cm caudally and 1-cm cranially from the center of the
lesion) for histological analysis and stained with hematox-
ylin-eosin (HE) (4,5).
An experienced pathologist (not an author) performed the
microscopic evaluations and evaluated the following para-
meters: necrosis, hemorrhage, hyperemia, cellular infiltration
and axonal degeneration. These variables were scored as
zero (absence), 1 (discrete), 2 (moderate) and 3 (severe).
As described previously (4,5), the proximal and distal portions
of the spinal cordwere cut and fixed in osmium tetroxide solution
(2%) and then stained with toluidine blue (at 1%, Figure 2).
Two fields were selected from transverse sections of the spinal
cords; the sections were 2 microns thick and were located 1 mm
distal and 1 mm proximal from the center of the lesion. The
regenerated axon fibers were counted in the photos using the
Sigma Scan Pro 5.0 software; only neurons with a diameter
greater than or equal to 15 mm were considered during counting.
The following formula was used: IR = (number of axons in the
distal area/number of axons in the proximal area)  100.
Statistical analysis
The primary outcome considered in this study was the
BBB score on the 42nd day. The secondary outcomes were the
MEP and results of histological analysis (considered as a
subjective measure in the HE staining analysis and an
objective measure in the toluidine blue staining).
The continuous data were tested for normality using the
Kolmogorov-Smirnov test. If the distribution was normal,
Student’s t test was used for comparisons between groups.
The descriptive statistics were presented as the means and
standard deviations (SD). For the evaluation over time, an
analysis of variance (ANOVA) with repeated measures was
used. The ordinal data in the histological evaluation were
analyzed with the Mann-Whitney test. A Chi-squared test
was used to analyze the categorical data.
The Statistical Package for Social Sciences (SPSS) software,
version 19.0 for Windows, was used in the statistical
analysis. P-values that were less than or equal to 0.05 were
considered significant.
’ RESULTS
There was no death in any of the groups before the 42nd
day. It was possible to obtain complete spinal cord lesions in
all rats. Autopsy revealed no empyema or condensation in
the abdomens and lungs and no cases of neurogenic bladder,
hyperemia or hematuria were detected. The SCI was effective
in all animals and all rats were included in the analyses.
After SCI, the week-by-week BBB scores showed evident
improvements in the functional evaluation of all rats from the
fourth week through the end of the study (p=0.038), although
significantly better scores were observed in the experimental
group of rats, which received the estrogen treatment (Table 1).
The MEP evaluation also showed an enormous difference
between the treated and untreated animals. After SCI, the
estrogen-treated rats performed significantly better than the
control rats, considering both the latency (time taken from
the impulse to be transmitted from the head to the limbs;
p=0.000) and amplitude values (a reflection of the number of
axonal fibers involved in the impulse transmission; p=0.007)
(Table 2). The exam showed that in the estrogen-treated rats,
the electric impulse travelled more than 17 times faster
between the limbs and the head, with a 7-fold increase in
amplitude. In the control group, 50% of the rats had no
response of any type in the MEP. However, there was a bit
Figure 1 - Anesthetized Wistar rat undergoing functional
evaluation with the motor evoked potential test after experi-
mental spinal cord lesion.
Figure 2 -Moderate cellular infiltration and cystic degeneration of
the spinal cord tissue in a Wistar rat submitted to experimental
spinal cord injury (40 x magnification, hematoxylin-eosin staining).
The image refers to the animal number 7 from the estrogen group.
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of noise in both the average latency and amplitude values.
We performed a comparative analysis of the latency between
groups, substituting the value of 100 ms with 500 ms for the
5 rats in the control group (time observed in the latency
analysis) and the average value was reduced. However, the
estradiol-treated group still showed the lowest latency, with
a statistically significant difference (po0.05) compared to the
control group (data not shown).
There was no significant difference between groups in the
histological tissue analysis for the following variables: necrosis,
hemorrhage, hyperemia, axon degeneration (by HE) and
cellular infiltration (Table 3). Figure 3 shows examples of the
tissue abnormalities after SCI. In the axon analysis with
toluidine blue staining, the control group had a significantly
lower neuron count than the treated group. The diameter of the
axons was also significantly smaller in the control group
compared to the estrogen-treated group (Table 4).
’ DISCUSSION
The effects of estrogen in nerve regeneration or protection
have been studied throughout the last decade using various
experimental models (7-10,13,16) and the results have shown
the benefits of this hormone in different outcomes. In brain cells,
estrogen protects against glutamate-induced cell death and
oxidative stress. Estrogen also improves recovery after traumatic
brain injury, cerebral ischemia and peripheral nervous system
lesions (12). The neuroprotective effects of estrogen are evident
both before and after the neurological lesion, as well as in
advanced phases of neurological tissue damage (8,16).
This study is the first to analyze functional recovery using
two instruments (the BBB evaluation and the MEP exam) and
two different histological evaluations. The follow-up period was
also extended to six weeks, similar to the study by Hubscher et
al. (16) In their study, the functional results in the treated group
persisted throughout the follow-up period. Similar studies
(7-10,13,16) have also demonstrated benefits from the same
dosage of estrogen (4 mg/kg) in rats with SCI (7-9). The
findings in this study are consistent with the most recent
scientific literature (7-10,12,13,16-19) and our study is original
because it combines histological and functional analysis.
This study showed significantly higher BBB scores beginning
at the fourth week following SCI, which is different from
the findings reported by Yune et al. (10) and Ritz and
Hausmann (8), where the animals improved earlier. The latter
study actually reported lower scores after the fourth week. In
addition, the animals in the study by Sribnick et al., 2005 (7),
were sacrificed at 48 hours after SCI, whereas in this present
study, the animals were sacrificed only at the end of the sixth
week and they still maintained the benefits of estradiol
administration. Longer-lasting benefits of estrogen therapy
were also reported in the study by Hubscher et al., 2010 (16),
which also extended the experiment until the sixth week after
injury. Olsen et al. (13) administered estrogen for 21 days after
SCI and obtained good cellular physiology results.
A single dose of estrogen was used in this experiment and
the benefits were only observed beginning at the fourth
week. Other authors (8,10,13) have administered estrogen for
longer periods and obtained good cellular physiology
results. One possible explanation for the excellent results of
estrogen administration in our study is that a higher dose
was used soon after the lesion was induced (11). Therefore,
although this study provides new evidence for the benefits of
estrogen in SCI in three different outcomes, one limitation
of our experiment is that the early versus late administration
of the drug was not tested. Instead of using a single dose of
Table 1 - Mean BBB scores in the treated and control groups for
each week (n=10 for each group).
Group Mean Standard deviation p
Week 1 Estradiol 0.6 0.699 0.791
Control 0.7 0.949
Week 2 Estradiol 1.8 1.317 0.159
Control 2.9 1.969
Week 3 Estradiol 5.2 1.989 0.082
Control 3.7 1.636
Week 4 Estradiol 8.1 2.726 0.038
Control 5.7 2.003
Week 5 Estradiol 11.4 2.951 0.014
Control 8.5 1.269
Week 6 Estradiol 15.1 2.132 0.000
Control 9.3 1.494
Figure 3 - Photomicrograph showing spinal cord tissue stained
with toluidine blue in a Wistar rat submitted to experimental
spinal cord injury (100 x magnification). Viable axon neurons are
stained blue for evaluation.
Table 2 - Amplitude and latency values obtained in the evoked
potential test in the hind limbs of the rats in each group.
Group Mean Standard deviation p
Latency Estradiol 3.68 0.80 0.000
Control 53.06 48.16
Amplitude Estradiol 14.34 16.90 0.007
Control 2.91 0.95
Table 3 - Means and standard deviation of the histological




Necrosis Estradiol 1.90 0.568 0.125
Control 1.50 0.527
Hemorrhage Estradiol 1.90 0.568 0.957
Control 1.90 0.316
Hyperemia Estradiol 2.30 0.823 0.188
Control 1.90 0.568
Axon degeneration Estradiol 1.60 0.843 0.619
Control 1.70 0.675
Cellular infiltration Estradiol 1.70 0.949 0.813
Control 1.80 1.033
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estrogen, a prolonged treatment period might have produced
even stronger results. According to Sribnick et al. (9), even
chronic cases of SCI seem to show motor function improve-
ment after estrogen therapy. However, the early versus late
benefits of estrogen administration could not be evaluated
due to the study design.
The current study highlights the pioneer use of the MEP
test in experiments with estrogen; this approach represents a
more objective evaluation of functional results than does the
BBB test because the BBB test is observer-dependent. The
speed at which the electric signal from the neuron travels,
expressed as latency and the ability of the fibers to recover,
expressed by the amplitude, are clinically correlated with
clinical exams and the MEP is not limited in cases of anterior
spinal cord syndromes, as is the somato-sensitive exam (6).
Therefore, the MEP test is a promising tool in future studies
on the effect of estrogen in SCI recovery.
Specifically, in this study, the MEP results obtained in the
control group (higher latency and lower amplitude values)
may serve as a direct and objective indicator of the trauma to
the spinal cord. The higher latency in the control group
compared with the estrogen group could be due to a loss of
myelin, which, in turn, is a consequence of the neural tissue
damage and compromised microcirculation. Moroever, the
lower amplitude values in the control group compared to
those in the treated group may be the ultimate consequence
of axonal degeneration after the primary and secondary
changes in the neural tissue (including neuronal death and
apoptosis), leading to a reduction in the number of
functioning neurological paths (axons).
Another important feature of our study is that in addition
to the histological analysis of necrosis, hemorrhage, hyper-
emia and cellular infiltration with HE staining, which
confirmed the generation of SCI, toluidine blue was used
to count the axons and neurons in a much more objective
evaluation (20). The HE staining did not show significant
differences in necrosis, hemorrhage, hyperemia, axon degen-
eration or cellular infiltration between the treated rats and
the controls, which is likely because the HE evaluation was
not sensitive enough to detect the effects of a moderate lesion
caused by the NYU Impactor (5). One could criticize the
scoring system used in this study for the histological
evaluation of necrosis, hemorrhage, hyperemia and cellular
infiltration; indeed, this analysis is subject to some bias in the
personal evaluation of the slides, even when using a scoring
system. However, no other objective evaluation of the
presence of these histological variables is currently available.
Nevertheless, the axon and neuron counts, which represent a
much more objective evaluation, showed significant differ-
ences that might explain the functional recovery observed in
the rats receiving estrogen.
Science is unraveling promising frontiers in the treatment
of SCI, a field with limited resources beyond palliative care.
Animal models are important tools in the search for effective
treatments. Future studies using 17-beta estradiol, a widely
available endogenous hormone and sensitive and objective
evaluation tests could possibly provide results that would
allow the initiation of tests with humans. Moreover, it is
necessary to examine different dosages and times of
administration, similar to the doses that have already been
proven safe in clinical use (such as those typically used with
estrogen replacement therapy) to accelerate the translation of
17-beta estradiol as a therapeutic intervention for use in SCI
patients. Additionally, the investigation of non-feminizing
congeners of 17-beta estradiol, such as 17-alpha estradiol,
could be useful.
The administration of estrogen immediately after SCI
showed neuroprotective effects, as demonstrated by func-
tional motor recovery of the treated animals, beginning at the
fourth week after lesion formation. The hypothesis of a
neuroprotective effect of estrogen was confirmed by the
functional evaluations, but not by the tissue histological
evaluations.
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